Every material Form 8-K Zenas BioPharma, Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Zenas BioPharma filed a new prospectus supplement for an at-the-market offering of up to $200 million in common stock through Jefferies LLC, and ended the earlier program, under which it had sold about $153.2 million of shares with about $46.8 million unsold. The filing is a routine share-sale mechanism, and any sales would dilute existing shareholders, though the filing does not state whether or when any shares will be sold.
New prospectus supplement filed November 6, 2026, for up to $200,000,000 of common stock under the October 8, 2025 Sales Agreement with Jefferies LLC
Prior program terminated: about $153.2 million sold and about $46.8 million unsold at filing date
Shares to be offered under the existing Form S-3ASR registration statement, which became automatically effective upon filing
Ropes & Gray LLP legal opinion filed as Exhibit 5.1
Zenas BioPharma reported results for the quarter ended September 30, 2026. Revenue was $10.0 million, tied to a development milestone under its Bristol-Myers Squibb agreement, compared with none a year earlier. The net loss widened to $108.9 million, or $1.65 per share, from $51.5 million, or $1.22 per share, as research, development and administrative costs rose.
Revenue was $10.0 million, from a development milestone under the Bristol-Myers Squibb license and collaboration agreement; no revenue was recognized in the prior-year quarter.
Net loss was $108.9 million, or $1.65 per share, versus $51.5 million, or $1.22 per share, a year earlier.
R&D expenses were $58.5 million (up from $34.4 million) and G&A expenses were $27.4 million (up from $13.2 million).
Cash, cash equivalents and investments were $647.1 million as of September 30, 2026; the FDA set a PDUFA target action date of May 27, 2027 for obexelimab in IgG4-RD.
Zenas BioPharma announced on October 12, 2026 new data from its Phase 3 INDIGO trial of obexelimab in IgG4-related disease, presented at the 6th International Symposium on IgG4-Related Disease. The filing includes open-label extension flare and safety results, a glucocorticoid toxicity analysis, and initial vaccine response findings, which the company says add to the clinical evidence for obexelimab.
Estimated 12-month probability of remaining flare-free was 0.93 (adjudicated flares) and 0.87 (investigator-determined flares), with five patients pending adjudication.
Obexelimab significantly reduced cumulative glucocorticoid toxicity versus placebo at week 52 (GTI Cumulative Worsening Score difference -11.4; p=0.021).
In a vaccine sub-study, 6 of 7 (86%) participants reached influenza seroimmunity and 4 of 4 (100%) reached COVID-19 seroimmunity during a treatment-free window.
Phase 2 SunStone trial of obexelimab in systemic lupus erythematosus has topline results expected in 4Q 2026.
Zenas BioPharma reported a second-quarter 2026 net loss of $111.5 million, up from $52.2 million a year earlier, as research and development and acquired in-process research costs rose. The company also said CFO Jennifer Fox will move to a strategic advisor role to the Board Chair on September 30, 2026, and that Christy Oliger was appointed to the board effective September 1, 2026.
Q2 2026 revenue was $1.0 million, tied to a development milestone, versus none in Q2 2025.
R&D expenses rose to $62.9 million from $43.0 million, and acquired in-process R&D expenses were $30.0 million.
Cash, cash equivalents and investments were $673.9 million as of June 30, 2026.
Joe Farmer, President and COO, will serve as principal financial and accounting officer until a CFO is appointed.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Zenas BioPharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →